Perth Biosciences Collaborates with Japan’s Scrum Corporation for Distribution
Perth Biosciences, a pioneering leader in the accessibility and scalability of single-cell sequencing, has officially announced a strategic agreement with Tokyo-based Scrum Inc., a premier distributor of life sciences and biotechnology solutions in Japan. This partnership is set to significantly enhance Perth’s presence within Japan’s research community by providing academic and industrial researchers with full access to Perth’s innovative single-cell sequencing solutions.
The demand for advanced single-cell sequencing technologies has been rapidly increasing across Asia, particularly in biotechnology, pharmaceutical, and academic research sectors. Perth Biosciences’ Evercode™ single-cell sequencing solution has gained widespread recognition due to its simplicity, scalability, and ability to provide high-resolution insights into cellular heterogeneity. Through this collaboration, Scrum will play a pivotal role in ensuring that researchers in Japan can efficiently utilize Perth’s state-of-the-art single-cell sequencing technologies to accelerate discoveries in various fields such as oncology, immunology, neurobiology, and genetic disorders.
“Biotech, pharmaceutical, and academic researchers across Asia are rapidly adopting our single-cell sequencing solution, Evercode™, due to its scalability and simplicity,” said Dr. Alex Rosenberg, CEO and co-founder of Perth Biosciences. “Our partnership with Scrum will enable researchers in Japan to easily leverage our advanced single-cell sequencing solution to accelerate discovery and push the boundaries of biomedical research.”
As part of the agreement, Scrum Inc. will serve as the exclusive distributor of Perth Biosciences’ comprehensive portfolio of single-cell solutions throughout Japan. These solutions include:
- Evercode™ Cell and Nuclei Fixation: A solution designed for streamlined single-cell and single-nucleus sample preparation.
- Evercode™ Whole Transcriptome: Enables high-throughput single-cell RNA sequencing for capturing comprehensive gene expression data.
- Evercode™ TCR: A targeted approach for profiling T-cell receptor (TCR) diversity and understanding immune responses.
- Evercode™ BCR: A specialized solution for analyzing B-cell receptor (BCR) repertoires, aiding in antibody discovery and immune system characterization.
- CRISPR Detect: A tool for high-resolution single-cell CRISPR screening applications, providing valuable insights into gene editing outcomes.
- Gene Select: Allows for targeted single-cell sequencing, offering cost-effective solutions for specific gene panels.
- Trailmaker™: A bioinformatics platform designed to simplify single-cell data analysis, making it more accessible and interpretable for researchers.
This strategic collaboration aligns with Perth Biosciences’ ongoing global expansion efforts. The company has already established strong footholds in key international markets, including South Korea, Singapore, and India, while also experiencing robust growth in North America, Europe, Australia, Israel, and New Zealand. The partnership with Scrum marks a significant step forward in further solidifying its presence within the Japanese scientific community.
Japan has long been a leader in single-cell research, with numerous scientists making groundbreaking contributions to the field. By partnering with Scrum, Perth Biosciences aims to provide Japanese researchers with direct access to its cutting-edge technologies, enabling them to explore new frontiers in biomedical research.
“Japan is at the forefront of single-cell research, with many scientists making significant contributions to the field,” said Kenji Nishimoto, CEO of Scrum Inc. “Our partnership with Perth Biosciences will provide Japanese researchers with unprecedented access to state-of-the-art single-cell sequencing technologies, empowering them to achieve groundbreaking scientific advances. This collaboration will support our mission to bring the most advanced and innovative scientific tools to the research community in Japan.”
The Evercode™ technology developed by Perth Biosciences has revolutionized single-cell sequencing by offering an innovative barcoding system that enables researchers to scale their experiments without compromising data quality. This breakthrough has made high-throughput single-cell sequencing more accessible to a wider range of laboratories, including those with limited resources. The technology’s ability to process millions of cells simultaneously provides unparalleled resolution and insights into cellular behavior, making it an invaluable tool in various research applications.
Scrum Inc. is well known for its expertise in distributing advanced life sciences technologies to researchers in Japan. With a strong network across academic institutions, pharmaceutical companies, and biotechnology firms, Scrum is uniquely positioned to ensure that Perth Biosciences’ solutions reach the right researchers and institutions, maximizing their impact within the Japanese research ecosystem.
As the global demand for single-cell sequencing continues to grow, collaborations like this one between Perth Biosciences and Scrum Inc. are essential for advancing scientific discovery. By making cutting-edge technologies more accessible, this partnership will enable researchers to accelerate their studies, uncover novel biological insights, and develop innovative therapeutic strategies for various diseases.
Moving forward, Perth Biosciences and Scrum Inc. plan to host joint workshops, training sessions, and scientific symposiums to educate and support Japanese researchers in adopting and optimizing single-cell sequencing techniques. These initiatives will foster knowledge exchange and strengthen the collaboration between Perth, Scrum, and the broader Japanese research community.
This agreement represents a pivotal milestone for both companies, highlighting the growing importance of single-cell sequencing in biomedical research. Through their combined expertise and shared vision, Perth Biosciences and Scrum Inc. are poised to drive innovation and empower researchers in Japan to make transformative scientific discoveries that have the potential to impact human health worldwide.
